Received Jul 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | KH9KK | — |
Administration during pregnancy; Inappropriate age at vaccine administration; This non-serious retrospective pregnancy case was reported by a other health professional via call center representative and described the occurrence of vaccine exposure during pregnancy in a 41-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) suspension for injection (batch number KH9KK with expiry date 16-JAN-2027) for prophylaxis. On 27-JAN-2026, the patient received the 1st dose of Arexvy. On 27-JAN-2026, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: Inappropriate age at vaccine administration). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: Administration during pregnancy). The outcome of the vaccine exposure during pregnancy and inappropriate age at vaccine administration were not applicable. Pregnancy exposure: Pregnancy Exposure (Arexvy): To mother in third trimester Pregnancy Details (Neonate 1): Number of Fetuses/Neonates: 1 Pregnancy Outcome: Live neonate with no apparent congenital anomaly Additional Information: GSK receipt date 30-JUN-2026 The Arexvy vaccine was administered to pregnant patient back in January 2026 at 35 weeks. The patient delivered on February, 2026. The reporter consented to follow up.